GlobeNewswire

Basilea announces partial repurchase offer for at least CHF 90 million and up to CHF 110 million in principal amount of its outstanding convertible bonds due 2022

Share

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

Basel, Switzerland, June 25, 2020

Basilea Pharmaceutica Ltd. (SIX: BSLN, the “Offeror”) announces the publication of a partial repurchase offer of at least CHF 90 million and up to CHF 110 million in principal amount of its outstanding convertible bonds due 2022 (the "Repurchase Offer"). The Repurchase Offer price amounts to 100.50% of par plus accrued and unpaid interest. The cooling-off period during which no tenders are accepted commences on 26 June 2020 and ends on 9 July 2020. The tender offer period is expected to commence on 10 July 2020 and to expire on 16 July 2020 at 4pm CEST. The settlement date is expected to occur on July 28, 2020. The bonds are listed and traded at SIX Swiss Exchange (ISIN: CH0305398148; SSN: 30'539'814) (the "Bonds"). 

The tender offer is submitted after yesterday's successful launch, provisional allocation and pricing of CHF 125 million senior unsecured convertible bonds due 2027 (the “New Bonds”). The New Bonds serve to finance the Repurchase Offer. The New Bonds are not finally allocated and such allocation will depend on the successful repurchase under the Repurchase Offer. The Offeror may clawback New Bonds in an amount of up to CHF 25 million subject to the principal amount of Bonds tendered in the Repurchase Offer. Moreover, the conversion price of the New Bonds will only be determined in a delta placement of existing shares of the Offeror after the end of the offer period under the Repurchase Offer. The Repurchase Offer is therefore subject to:

  • the delta placement resulting in a reference price, i.e. the price to which the conversion premium is added to obtain the conversion price; and
  • the conversion price of the New Bonds being at least CHF 46.9993; and
  • the placement of the New Bonds in the minimal amount of CHF 100,000,000 in principal amount and the valid tender of at least CHF 90,000,000 in principal amount of the Bonds.

The Company will only accept for purchase Bonds up to a maximum of aggregate principal amount being the lower of (i) CHF 110,000,000 and (ii) the aggregate principal amount of the New Bonds minus CHF 10,000,000.

Up to CHF 110 million of the Bonds due 2022 shall be repurchased and up to CHF 125 million New Bonds due 2027 shall be sold to allow the Offeror to improve its debt maturity profile. Whilst the transaction does not significantly change the total amount of outstanding debt of the Offeror, it shifts the maturity of approximately 50% of the total outstanding debt significantly beyond 2022.

This Press Release is not an offer for the repurchase of the Bonds, but only discloses the most important terms of the planned repurchase offer. The Repurchase Offer is only addressed to eligible holders of the Bonds by the Notice of Repurchase Offer published on the website of the Offeror.

About Basilea

Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.

Disclaimer

This Repurchase Offer does not constitute an offer or an invitation to participate in the Repurchase Offer in any jurisdiction in which, or to any person to or from which, it is unlawful to make such invitation or for there to be such participation under applicable securities laws. The distribution of this press release in certain jurisdictions may be restricted by law. Persons into whose possession this press release comes are required to inform themselves about, and to observe, any such restrictions.

No action has been or will be taken in any jurisdiction in relation to the Repurchase Offer that would permit a public offering of securities in any such jurisdiction.

United States

The Repurchase Offer is not being made, and will not be made, directly or indirectly, in or into, or by use of the mail of, or by any means or instrumentality of interstate commerce of or of any facilities of a national securities exchange of, the United States or to or for the account or benefit of, U.S. persons as defined in Regulation S of the Securities Act (each a "U.S. person"). This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone and the internet and other forms of electronic communication. The Bonds may not be tendered for purchase pursuant to the Repurchase Offer by any such use, means, instrumentality or facility from or within the United States or by any persons located or resident in the United States as defined in Regulation S of the U.S. Securities Act of 1933, as amended (the "Securities Act") or to U.S. persons. Accordingly, copies of the Repurchase Offer Notice and any other documents or materials relating to the Repurchase Offer are not being, and must not be, directly or indirectly, mailed or otherwise transmitted, distributed or forwarded (including, without limitation, by custodians, nominees or trustees) in or into the United States or to persons located or resident in the United States or to U.S. persons. Any purported offers to tender Bonds pursuant to the Repurchase Offer resulting, directly or indirectly, from a violation of these restrictions will be invalid, and any purported tender of Bonds made by a U.S. person, a person located or resident in the United States or from within the United States or from any agent, fiduciary or other intermediary acting on a non-discretionary basis for a principal giving instructions from within the United States or any U.S. person will not be accepted.

Each Bondholder participating in the Repurchase Offer will represent to the Offeror, the Joint Dealer Managers and the Tender Agent that it is not located or resident in the United States and is not a U.S. person and is not giving an order to participate in the Repurchase Offer from within the United States or on behalf of a U.S. person.

United Kingdom

The communication of the Repurchase Offer Notice and any other documents or materials relating to the Repurchase Offer is not being made and such documents and/or materials have not been approved by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000, as amended. Accordingly, such documents and/or materials are not being distributed to, are not directed at and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to persons within the United Kingdom falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order”)) or falling within Article 43(2) of the Order, or to other persons to whom it may lawfully be communicated (together “relevant persons”). The investment activity to which this document relates will only be engaged in with relevant persons and persons who are not relevant persons should not rely on it.

European Economic Area

In any Member State of the European Economic Area (the "EEA") or in the United Kingdom (each, a "Relevant State"), the Repurchase Offer is only addressed to, and is only directed at, qualified investors in that Relevant State within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation"). Each person in a Relevant State who receives any communication in respect of the Repurchase Offer contemplated in the Repurchase Offer Notice will be deemed to have represented, warranted and agreed to and with the Joint Dealer Managers, the Tender Agent and the Company that it is a qualified investor within the meaning of the Prospectus Regulation. The Bonds have not been admitted to trading on a regulated market in the European Economic Area or in the United Kingdom.

Switzerland and General

This document and the Repurchase Offer Notice neither constitute a prospectus within the meaning of Articles 652a and 1156 of the Swiss Code of Obligations (as in effect immediately prior to the entry into force of the FinSA) nor a prospectus within the meaning of the listing rules of the SIX Swiss Exchange, a prospectus within the meaning of the FinSA or under any other applicable laws.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Galapagos increases share capital through subscription right exercises18.9.2020 22:01:00 CESTPress release

Mechelen, Belgium; 18 September 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 86,280 new ordinary shares on 18 September 2020, for a total capital increase (including issuance premium) of €2,403,087. Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 subscription rights. Three other management board members exercised an aggregate number of 15,000 subscription rights. In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €353,435,739.72, the total number of securities conferring voting rights amounts to 65,340,842, which is also the tota

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS18.9.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Government Bonds, 2020-09-25 Maturity dateLoanISIN codeCouponVolume, SEK million2029-11-121061 SE00112819220.75 %1,000 +/- 2502032-06-01 1056 SE00045172902.25 %1,000 +/- 250 Settlement date 2020-09-29 Bids have to be entered by 10.00 on SEP 25, 2020 Highest permitted bid volume: 1 000 million in issue SGB 1061 and 1 000 SEK million in issue SGB 1056 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST)ON SEP 25, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS18.9.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Covered Bonds, 2020-09-24 Maturity dateLoanISIN codeCouponVolume, SEK million2022-04-08 5531 SE00069912461.00 %1,000 +/- 5002022-12-21 575 SE00105465721.50 %1,000 +/- 500 2022-09-211586SE00031748384.50 %1,000 +/- 5002022-06-15191SE00075256541.00 %1,000 +/- 5002022-12-212212SE00102970851.00 %400 +/- 2502022-09-21515SE00072784292.25 %400 +/- 2502022-06-15143SE00085866551.25 %400 +/- 250 Settlement date 2020-09-28 Bids have to be entered by 10.00 on SEP 24, 2020 Highest permitted bid volume: 1,000 SEK million in issue 5531 1,000 SEK million in issue 575 1,000 SEK million in issue 1586 1,000 SEK million in issue 191 400 SEK million in issue 2212 400 SEK million in issue 515 400 SEK million in issue 143 Maximum volume 5 billion SEK in total Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON SEP 24, 2020. For more information, please con

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS18.9.2020 16:20:00 CESTPress release

Sveriges Riksbank CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS Bid procedure on 22 September 2020, Municipalities and Regions Bonds: Floating-Rate Notes (FRN) issued in SEK by Municipalities or Regions with maturity in 2025. The following issuers are accepted for delivery: Göteborgs KommunJönköpings KommunMalmö KommunNorrköpings Kommun Skåne Läns LandstingStockholms KommunSundsvalls KommunTäby KommunUppsala KommunVästerås KommunÖrebro KommunÖstersunds Kommun Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after 11 September 2020. Bids: Bids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se. Bid date: Tuesday 22 September 2020 Bid time: 1000-1100 hours (CEST) on the Bid date Requested volume: (corresponding nominal amount) SEK 750 +/- 750 million Highest permitted bid vol

Karolinska Development’s portfolio company OssDsign strengthens patent coverage for OssDsign Cranial PSI in key market18.9.2020 16:04:55 CESTPress release

STOCKHOLM, SWEDEN – September 18, 2020. Karolinska Development (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has received a notice of allowance from the United States Patent and Trademarks Office (USPTO) concerning the implant design for the company’s product Cranial PSI, thus strengthening the patent protection for the technology in the company’s most important market in the US. The patent covers the implant, its support structure, as well as the method of making customized implants for each patient. Approvals of the patent were given in the European and Japanese markets last year and in Australia earlier in 2020. With the allowance in the US, a stronger patent protection for OssDsign Cranial PSI is thus established in all key markets. The patent family is valid until 2035 and builds upon a broad international patent portfolio. “The notice of allowance granted by the USPTO is an important final step in securing the patent protection for the technology behind O

Karolinska Developments portföljbolag OssDsign stärker patentskyddet på huvudmarknad för OssDsign Cranial PSI18.9.2020 16:04:55 CESTPressemelding

STOCKHOLM, SVERIGE 18 september 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget OssDsign har givits ett godkännande av det amerikanska patentverket (USPTO) för ett patent relaterat till designen av bolagets produkt Cranial PSI. Genom godkännandet stärks patentskyddet för sin teknologi på bolagets viktigaste marknad USA. Patentet täcker implantatet, dess förstärkande struktur, samt metoden att tillverka ett patientspecifikt implantat. Bolaget erhöll patentskydd för produkten i Europa och Japan under föregående år och i Australien under början av 2020. Med godkännandet från den amerikanska myndigheten har nu bolaget etablerat ett starkt patentskydd för Cranial PSI på samtliga nyckelmarknader. Patentfamiljen, som är giltig till 2035, förstärker OssDsigns redan omfattande internationella patentskydd. ”Godkännandet från USPTO är ett viktigt sista steg för att säkerställa ett patentskydd för teknologin bakom OssDsigns Cranial PSI på alla viktiga mar